Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
JEZ-567 by Novartis for Refractory Acute Myeloid Leukemia: Likelihood of Approval
JEZ-567 is under clinical development by Novartis and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...
Data Insights
JEZ-567 by Novartis for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
JEZ-567 is under clinical development by Novartis and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...